Recent advances in engineered nanozymes for precision lung cancer therapy Authors: Fushuang Zheng, Hongyan Zhang, Feng Guo, Xiajie Wu, Kuanbing Chen, Nana Li, Hengyi Yan Published: 2026 ABSTRACT AbstractLung cancer therapy remains constrained by adaptive resistance and the inability of current modalities to effectively reprogram the tumor microenvironment (TME). Nanozymes introduce a catalytic paradigm that converts intrinsic TME features into therapeutic leverage. Here, we frame nanozymes not merely as drug carriers but as active regulators of tumor biology, capable of rewiring redox homeostasis, disrupting metabolic dependencies, and amplifying antitumor immunity. Through catalytic generation of reactive species, oxygen modulation, and cascade reactions, nanozymes sensitize tumors to chemo-, radio-, and photo-based therapies while promoting immunogenic cell death. This review further highlight design logic centered on catalytic programmability and spatiotemporal activation, and discuss the key barriers to clinical translation, defining a roadmap toward next-generation catalytic nanomedicine.Keywords: Nanozymes, Lung cancer, Biomaterials, Drug delivery, Target therapy Introduction Lung cancer represents a paramount global health challenge, standing as the leading cause of cancer-related mortality worldwide [[1], [2], [3], [4]]. It is a disease defined by profound heterogeneity at both the clinical and biological levels. Pathologically, it is primarily dichotomized into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with NSCLC accounting for the majority of cases [[5], [6], [7]]. However, even within this classification, significant inter-patient variability exists, driven by distinct driver mutation landscapes, unique clonal evolutionary trajectories, and diverse tumor microenvironments (TMEs) [[8], [9], [10]]. The therapeutic management of lung cancer is complicated by a confluence of factors, including a high proportion of patients diagnosed at advanced stages, the challenge of identifying early micro metastases, and the frequent presence of underlying chronic pulmonary comorbidities [[11], [12], [13]]. While the advent of molecularly targeted therapies and immune checkpoint inhibitors (ICIs) over the past decade has markedly improved survival for specific patient cohorts, overall therapeutic efficacy remains constrained [[14], [15], [16]]. Key obstacles include intrinsic and acquired drug resistance, formidable microenvironmental barriers such as hypoxia and acidosis, insufficient drug penetration due to a dense stromal matrix and high interstitial fluid pressure, and limitations on combination strategies imposed by systemic toxicities [17]. The current standard-of-care integrates surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy according to disease stage [18]. Surgery offers a curative opportunity for early-stage patients yet struggles to eradicate latent micro metastases, leaving a substantial risk of postoperative recurrence. Radiotherapy continues to advance through precision imaging and dose sculpting, but its efficacy is frequently attenuated by tumor hypoxia, adaptive reactive oxygen species (ROS) metabolism, and enhanced DNA damage repair mechanisms [19]. Cytotoxic chemotherapy, such as platinum-based doublets, provides benefits across various stages but is often hampered by myelosuppression, neurotoxicity, and the development of multidrug resistance [20]. Targeted agents can elicit rapid and profound responses in molecularly defined populations, yet their durability is often undermined by the activation of bypass signaling pathways, secondary resistance mutations, epithelial-mesenchymal transition, and histological transformation [21]. Although ICIs have transformed long-term outcomes for a subset of patients, their broader utility is constrained by modest overall response rates, heterogeneous responses between lesions, and the occurrence of immune-related adverse events (irAEs) [22]. Consequently, there is an urgent and unmet clinical need for novel therapeutic platforms capable of remodeling the TME, targeting otherwise undruggable biological vulnerabilities, achieving spatiotemporally controlled synergism, and ensuring systemic safety [23,24]. Against this backdrop, nanozymes—nanomaterials engineered with intrinsic enzyme-like catalytic activities have emerged as a disruptive and powerful paradigm poised to redefine the boundaries of cancer therapy [[25], [26], [27], [28]]. Unlike their natural counterparts, nanozymes exhibit exceptional stability under harsh conditions, tunable catalytic activity, and are amenable to cost-effective, large-scale production [[29], [30], [31]]. Critically, their utility extends far beyond simple catalysis. They serve as versatile platforms that can be exquisitely designed to respond to specific stimuli within the lung TME, such as acidic pH, elevated hydrogen peroxide (H2O2) levels, hypoxia, and glutathione (GSH) overexpression [[32], [33], [34], [35]]. This stimulus-responsive activation enables an “intelligent” therapeutic strategy, confining potent cytotoxic activity to the tumor site, thereby dramatically enhancing therapeutic precision while mitigating collateral damage to healthy tissues [[36], [37], [38]]. Furthermore, the inherent multifunctionality of nanomaterials allows for the seamless integration of diagnostic imaging, targeted drug delivery, and multiple therapeutic modalities including chemodynamic therapy (CDT), photothermal therapy (PTT), photodynamic therapy (PDT), and immunotherapy into a single, all-in-one theranostic system [[39], [40], [41]]. This review aims to provide a comprehensive and critical overview of the latest breakthroughs in nanozyme-based strategies for the precision treatment of lung cancer. We will begin by dissecting the key pathological and molecular features of the lung TME that render it a fertile landscape for nanozyme-mediated interventions. Subsequently, we will systematically delineate how different classes of nanozymes are engineered to execute distinct therapeutic strategies, ranging from direct catalytic tumor ablation to sophisticated immunomodulation. A particular focus will be placed on nanozyme-centered combination therapies designed to elicit synergistic antitumor effects. Finally, we will critically analyze the formidable challenges impeding the clinical translation of these promising nanotechnologies and provide our perspective on the future directions that will shape the next generation of intelligent nanozyme-based therapies for lung cancer (Fig. 1). Schematic diagram of lung cancer treatment using chemotherapy, immunotherapy, and photothermal therapy based on different nanozymes. Molecular pathogenesis of lung cancer Lung cancer is not a monolithic entity but rather a complex constellation of pathological diseases, each defined by a distinct set of molecular characteristics [42]. Fig. 2 summarizes the causes and symptoms of lung cancer. Its initiation, progression, and evolution do not follow a simple linear narrative; instead, they are orchestrated by an intricate and dynamically interacting network of cells and molecules. A deep interrogation of this network's underlying logic is the cornerstone for developing next-generation precision therapies. This chapter aims to systematically deconstruct the three core pillars that drive the pathological course of lung cancer: first, the dysregulation of cellular redox homeostasis, known as oxidative stress; second, the profound remodeling of cellular energy and biosynthetic pathways, termed metabolic reprogramming; and third, the sophisticated strategies evolved by tumor cells to circumvent host immune surveillance, referred to as immune evasion. These three mechanisms are not isolated phenomena but are tightly interwoven into a synergistic network of cause and effect, which can often be traced back to a common set of upstream genetic driver events. We will elucidate how specific driver mutations act as the “prime movers,” not only dictating the intracellular signaling cascades but also shaping the tumor's unique metabolic phenotype, redox state, and mode of interaction with the immune system. A profound understanding of this complex pathological ecosystem not only uncovers the intrinsic vulnerabilities of lung cancer but also provides a robust theoretical framework and delineates clear therapeutic targets for the emerging nanozyme-based strategies discussed in subsequent chapters of this review. Diagram of the causes and symptoms of lung cancer. Driver mutations and core signaling pathways The molecular heterogeneity of lung cancer is largely shaped by recurrent driver alterations that activate oncogenic signaling, remodel tumor metabolism, and influence the TME [[43], [44], [45]]. In non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancer cases, actionable driver mutations have become the molecular basis for precision therapy [[46], [47], [48]]. Among them, epidermal growth factor receptor (EGFR) mutations and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations represent two of the most common and biologically distinct alterations in lung adenocarcinoma (LUAD) [[49], [50], [51]]. EGFR mutations are more frequently observed in non-smokers and Asian patients, whereas KRAS mutations are strongly associated with smoking history [[52], [53], [54]]. Other clinically relevant alterations, including ALK rearrangements, ROS1 fusions, ERBB2 mutations, MET exon 14 skipping or amplification, RET fusions, and PIK3CA mutations, further contribute to the molecular diversity of NSCLC and have promoted the development of targeted therapies [55]. Despite their diversity, many driver alterations converge on several core downstream pathways, particularly the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signaling cascades [56]. These pathways regulate cell proliferation, survival, metabolism, invasion, and therapeutic resistance [57]. Persistent activation of these signaling networks not only sustains malignant growth but also alters redox balance, energy metabolism, and immune interactions within the TME [58]. For example, oncogenic signaling can enhance glucose uptake, mitochondrial adaptation, antioxidant defense, and resistance to apoptosis, thereby creating biological vulnerabilities that may be exploited by nanozyme-based catalytic strategies [[59], [60], [61]]. Importantly, driver mutations also shape distinct immune and metabolic phenotypes, which is highly relevant to nanozyme-mediated precision therapy [[62], [63], [64]]. EGFR-mutant tumors often exhibit an immunologically “cold” phenotype characterized by low tumor mutational burden, limited immune-cell infiltration, and poor response to immune checkpoint inhibitors [65]. In contrast, KRAS-mutant tumors, particularly those associated with smoking-related mutagenesis, frequently display higher tumor mutational burden, stronger inflammatory signaling, and greater immune infiltration, although substantial heterogeneity remains [66]. These genotype-dependent differences suggest that nanozyme systems should not be viewed merely as broad-spectrum ROS-generating platforms. Instead, their rational design may need to consider mutation-associated redox status, metabolic dependence, and immune contexture [67]. For instance, EGFR-mutant cold tumors may benefit from nanozyme platforms that induce immunogenic cell death or remodel immunosuppressive TMEs, whereas KRAS-driven tumors with enhanced metabolic and oxidative stress may be more vulnerable to catalytic ROS amplification, glutathione depletion, or ferroptosis/cuproptosis-oriented strategies [[68], [69], [70], [71], [72]]. Therefore, driver mutations provide more than diagnostic and therapeutic biomarkers; they define biological contexts that may influence the efficacy of nanozyme-based interventions [73]. However, it should also be acknowledged that most current nanozyme systems remain TME-responsive rather than truly genotype-specific. Bridging driver mutation biology with catalytic nanomedicine remains an important direction for achieving more precise lung cancer treatment [74,75]. Table 1 summarizes the key driver genes in NSCLC and their associated phenotypic impacts. Table 1Key driver genes in NSCLC and their associated phenotypic effects.Table 1Driver alterationClinical characteristicsMajor biological featuresImmune/TME phenotypePotential nanozyme-relevant therapeutic vulnerabilityEGFR mutationCommon in non-smokers and Asian LUAD patientsEnhanced PI3K/AKT signaling, antioxidant adaptation, therapy resistanceImmune “cold” phenotype, low TMB, poor CD8+ T-cell infiltrationROS amplification, ICD induction, TME remodeling, hypoxia-targeted catalysisKRAS mutationSmoking-associated LUADMetabolic rewiring, oxidative stress dependence, glycolytic activationImmune “hot” phenotype, higher TMB, inflammatory signalingFerroptosis induction, GSH depletion, catalytic ROS therapyALK fusionYounger non-smokers with LUADStrong proliferative signaling and metabolic activationRelatively low immunogenicityCatalytic sensitization combined with targeted therapyMET amplification/exon 14 skippingFrequently associated with resistanceEnhanced invasion, survival, and metabolic plasticityImmunosuppressive tendencyCombination catalytic therapy and metabolic disruptionROS1 fusionRare NSCLC subsetRTK-driven survival signalingVariable immune infiltrationROS-mediated sensitizationRET fusionSmall subset of LUADPersistent MAPK and PI3K activationModerate immune activitySynergistic catalytic therapyKEAP1/NFE2L2 alterationFrequently co-occurs with KRAS mutationConstitutive antioxidant activation and redox adaptationImmunosuppressive high-redox phenotypeGSH depletion, ferroptosis/cuproptosis sensitizationTP53 mutationCommon co-mutation eventGenomic instability and apoptosis dysregulationIncreased oxidative stress heterogeneityROS amplification and DNA damage sensitization Key driver genes in NSCLC and their associated phenotypic effects. ROS imbalance and oxidative stress Oxidative stress, resulting from an imbalance between ROS generation and antioxidant defense, plays a central role in lung cancer initiation, progression, therapeutic resistance, and metabolic adaptation [[76], [77], [78]]. ROS, including superoxide anion (O2∙-), hydrogen peroxide (H2O2), and hydroxyl radicals (∙OH), are generated from mitochondrial respiration, oncogenic signaling, inflammatory stimulation, and environmental exposure such as cigarette smoke and radiation [[79], [80], [81]]. Under physiological conditions, antioxidant systems including glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) maintain redox homeostasis [[82], [83], [84]]. However, excessive ROS accumulation can induce DNA damage, lipid peroxidation, protein dysfunction, and genomic instability, thereby contributing to malignant transformation [[85], [86], [87]]. Compared with normal cells, lung cancer cells generally maintain persistently elevated ROS levels due to hyperactive metabolism, mitochondrial dysfunction, and sustained oncogenic signaling [[88], [89], [90], [91]]. To survive under chronic oxidative stress, tumor cells simultaneously upregulate antioxidant pathways to maintain ROS within a tolerable but pro-tumorigenic range [92]. This “adapted oxidative state” promotes proliferation, invasion, metabolic rewiring, and therapeutic resistance while avoiding ROS-induced cell death [93]. Such redox imbalance also creates an important therapeutic vulnerability for catalytic nanomedicine, since further ROS amplification may exceed the cellular tolerance threshold and trigger ferroptosis, apoptosis, or immunogenic cell death [94]. Among the regulatory pathways controlling redox homeostasis, the Nrf2-Keap1 axis is one of the most important in lung cancer [95]. Under oxidative stress, Nrf2 activation induces the transcription of antioxidant and detoxification genes, thereby enhancing cellular resistance to ROS-mediated damage [96]. In NSCLC, particularly lung squamous cell carcinoma, KEAP1 or NFE2L2 mutations frequently result in constitutive Nrf2 activation, leading to enhanced antioxidant capacity, metabolic adaptation, and resistance to chemotherapy, radiotherapy, and oxidative stress-inducing therapies [[97], [98], [99]]. Persistent Nrf2 activation is also associated with metabolic reprogramming through increased NADPH production and glutathione biosynthesis, supporting both redox homeostasis and rapid tumor proliferation [100,101]. Importantly, redox regulation is closely linked to the tumor immune microenvironment [[102], [103], [104]]. KEAP1/Nrf2-altered tumors often exhibit a highly reductive and immunosuppressive phenotype that impairs CD8+ T-cell activity and reduces responsiveness to immune checkpoint blockade [105]. These findings suggest that oxidative stress is not only a consequence of malignant transformation but also a key determinant of therapeutic sensitivity and immune regulation [106]. Therefore, modulation of ROS dynamics, antioxidant defense, and redox-dependent metabolic pathways has emerged as a major rationale for nanozyme-based lung cancer therapy [[107], [108], [109]]. Nanozyme systems capable of catalytic ROS amplification, glutathione depletion, oxygen modulation, or ferroptosis induction may exploit this intrinsic redox vulnerability to enhance therapeutic efficacy [110]. Tumor metabolic reprogramming In the 1920s, Otto Warburg observed a paradoxical phenomenon: unlike normal cells, which primarily rely on highly efficient mitochondrial oxidative phosphorylation to generate energy in the presence of oxygen, most tumor cells exhibit a preference for a seemingly “inefficient” mode of glucose metabolism. They rapidly convert glucose into lactate via glycolysis, even when oxygen is plentiful. This phenomenon, known as “aerobic glycolysis” or the “Warburg effect,” has since been established as a hallmark of cancer. This metabolic reprogramming is principally driven by a combination of oncogenic signaling pathways and the hypoxic conditions prevalent in the TME [[111], [112], [113]]. At the molecular level, cancer cells upregulate the glucose transporter GLUT1 to facilitate voracious glucose uptake [114,115]. They also modulate the expression and activity of key enzymes such as Hexokinase 2 (HK2), Pyruvate Kinase M2 isoform (PKM2), and Lactate Dehydrogenase A (LDHA) to channel the bulk of glucose flux toward lactate production [116]. The significance of the Warburg effect extends far beyond the rapid generation of ATP; critically, it diverts glycolytic intermediates into biosynthetic pathways for the production of nucleotides, amino acids, and lipids, thereby supplying the essential building blocks for rapid cell duplication. Moreover, the hypoxic microenvironment at the tumor core reinforces this metabolic shift through the stabilization of Hypoxia-Inducible Factor-1α (HIF-1α) [117]. HIF-1α acts as a “master switch” for metabolic reprogramming. Once activated, it binds to the hypoxia-response elements of hundreds of target genes, initiating a genetic program designed to adapt the cell to low-oxygen conditions [118]. Metabolically, HIF-1α is a potent driver of the Warburg effect. It directly upregulates the transcription of genes encoding nearly all key glycolytic enzymes, including GLUT1, HK2, PKM2, and LDHA. Concurrently, HIF-1α actively suppresses mitochondrial function by upregulating the expression of Pyruvate Dehydrogenase Kinase 1 (PDK1) [119]. PDK1 phosphorylates and inhibits the Pyruvate Dehydrogenase Complex, the critical gateway enzyme that catalyzes the entry of pyruvate into the tricarboxylic acid cycle. Through this “push-and-pull” mechanism, HIF-1α effectively rewires cellular metabolism, forcing a shift away from oxidative phosphorylation and toward aerobic glycolysis [120]. Multidimensional immune evasion strategies Although tumor cells harbor numerous mutations and should theoretically be recognized and eliminated by the immune system, lung cancer has evolved a sophisticated and multidimensional repertoire of strategies to evade immune surveillance [121]. At the level of the cancer cell itself, tumor cells downregulate the expression of Major Histocompatibility Complex (MHC) class I molecules [122]. This reduces the presentation of tumor antigens, rendering them less visible to cytotoxic T lymphocytes (CTLs) and allowing them to achieve a state of immunological “stealth.” A more active countermeasure involves the high expression of Programmed Death-Ligand 1 (PD-L1). When PD-L1 binds to the PD-1 receptor on the surface of T cells, it transmits a potent inhibitory signal that leads to T-cell exhaustion or even apoptosis [123]. Beyond these cell-intrinsic mechanisms, lung cancer excels at systematically remodeling the entire TMEs, converting it from an anti-tumor battlefield into a pro-tumorigenic sanctuary [124]. By secreting specific cytokines and chemokines, tumor cells recruit and activate a host of immunosuppressive cells, most notably regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) [125]. These inhibitory cells potently suppress the cytotoxic functions of CTLs and Natural Killer (NK) cells by secreting cytokines such as Transforming Growth Factor-β (TGF-β) and Interleukin-10 (IL-10), thereby constructing a formidable immunosuppressive network that shields the tumor from immune attack [126]. The pathological progression of lung cancer is not a mere summation of these mechanisms but rather a vicious cycle forged through their intricate dialogue and synergistic reinforcement. Metabolic reprogramming serves as the central hub connecting oxidative stress and immune evasion [127]. The massive quantities of lactate produced via the Warburg effect are actively extruded from cancer cells, leading to severe acidification of the TME [128]. This acidic environment is profoundly toxic to effector T cells, inhibiting their proliferation, metabolism, and cytokine secretion, thereby directly causing immunosuppression. Concurrently, the lactate-rich milieu promotes the inhibitory functions of MDSCs and Tregs and polarizes macrophages toward a pro-tumor M2 phenotype [129]. Oxidative stress, in turn, profoundly influences both metabolism and immunity. Persistent ROS can stabilize HIF-1α, thus exacerbating the Warburg effect and establishing a “ROS-HIF-1α-glycolysis” positive feedback loop [130]. Simultaneously, ROS can directly damage infiltrating immune cells and may induce the expression of PD-L1 on tumor cells, further intensifying immune evasion. Finally, closing this lethal loop, the successfully suppressed immune microenvironment gives rise to Tregs and MDSCs that secrete a variety of growth factors and cytokines. These factors not only deepen the state of immunosuppression but also act directly on cancer cells to promote invasion, metastasis, and angiogenesis, thus completing the fatal feedback cycle that drives the malignant evolution of lung cancer. Conventional treatment strategies and their limitations The therapeutic architecture of modern oncology is built upon several foundational pillars, which can be broadly categorized into modalities geared toward local control, such as surgery and radiotherapy, and those designed for systemic intervention, including chemotherapy, targeted therapy, and immunotherapy (Fig. 3). The evolutionary narrative of cancer treatment is, in essence, a history of relentless efforts to enhance therapeutic efficacy while striving to overcome the inherent limitations of preceding modalities. Although each treatment represents a significant medical advancement, its intrinsic constraints spanning biological, clinical, and socioeconomic dimensions have collectively propelled oncology toward a multi-modal, individualized treatment paradigm. These limitations are not merely side effects but fundamental challenges, including the inability to control micro metastatic disease, the emergence of cellular resistance, dose-limiting toxicities, and prohibitive treatment costs. Consequently, the contemporary standard of practice increasingly relies on combining multiple therapies to leverage synergistic effects, overcome resistance, and tailor treatment regimens to the specific characteristics of the patient and their tumor. Table 2 provides an overview of the core features of major cancer treatment modalities. Schematic diagram and limitations of traditional strategies for treating lung cancer. Table 2Characteristics and limitations of different traditional methods for treating lung cancer.Table 2Conventional therapyMajor therapeutic mechanismKey limitationsTumor microenvironment consequencePotential opportunity for nanozyme interventionSurgeryPhysical tumor removalLimited efficacy in advanced/metastatic diseaseResidual tumor recurrence and immune suppressionPostoperative catalytic immunomodulationChemotherapyCytotoxic inhibition of proliferating cellsDrug resistance, systemic toxicityElevated oxidative stress and antioxidant adaptationROS amplification, GSH depletion, drug sensitizationRadiotherapyDNA damage induced by ionizing radiationRadioresistance and hypoxia limitationIncreased hypoxia and redox imbalanceOxygen-generating nanozymes and catalytic radiosensitizationTargeted therapyInhibition of oncogenic driver signalingAcquired resistance and pathway reactivationMetabolic rewiring and survival adaptationCatalytic metabolic disruption and ROS sensitizationImmunotherapyReactivation of anti-tumor immunityLow response rate in immune-cold tumorsImmunosuppressive TMEICD induction and TME remodelingPDTROS generation under light activationOxygen dependence and limited penetrationHypoxia aggravationCAT-like oxygen-generating nanozymesPTTLocal hyperthermia-mediated tumor ablationHeat resistance and poor penetration depthStress adaptation and heterogeneous heatingHeat-enhanced catalytic therapy Characteristics and limitations of different traditional methods for treating lung cancer. Surgical therapy As the cornerstone of solid tumor management, surgery has long been the central modality for achieving curative intent. Its role in clinical practice is multifaceted, encompassing the entire continuum of care from diagnosis to treatment [131]. A primary function of surgery is to procure tissue samples via biopsy, which remains the “gold standard” for establishing a definitive pathological diagnosis [132]. Pathological analysis not only determines the tumor type and grade of malignancy but also provides critical molecular information essential for all subsequent treatment decisions. For localized solid tumors, radical resection is the principal therapeutic objective [[133], [134], [135], [136]]. The core principle is to achieve an “R0 resection” the complete excision of the primary tumor with a margin of surrounding normal tissue to ensure total clearance of the local disease. Ideal surgical technique avoids direct manipulation or incision of the tumor to prevent iatrogenic dissemination [137]. When a tumor has advanced to a stage where it is no longer curable, the goal of surgery shifts to improving the patient's quality of life. Palliative surgery aims to alleviate symptoms caused by the tumor, such as relieving bowel obstruction, controlling hemorrhage, or managing pain [138]. While conventional wisdom held that metastatic disease could not be cured by local means, modern surgical oncology has challenged this notion [139]. In carefully selected patients, the surgical resection of limited metastatic lesions can sometimes lead to long-term survival and even cure, particularly in cases like colorectal cancer with liver metastases or sarcoma with pulmonary metastases. Despite the indispensable role of surgery in achieving local control, its limitations are equally profound and fundamentally define the necessity for multi-modal therapy [140]. As a local treatment, the most fundamental limitation of surgery is its inability to address micro metastases cancer cells that have already spread via hematogenous or lymphatic routes but are too small to be detected clinically. These disseminated tumor cells may lie dormant in sites like the bone marrow or peripheral blood, often in a non-proliferative state, rendering them insensitive to standard chemotherapy that primarily targets dividing cells. These cells are the root cause of future recurrence [[141], [142], [143], [144]]. The detection of these occult tumor cells through high-sensitivity immunological or molecular methods is a powerful indicator of poor prognosis and provides the core rationale for postoperative adjuvant systemic therapy. Although the clinical significance of isolated tumor cells (ITCs, <0.2 mm) versus micro metastases (0.2-2.0 mm) remains debated across different cancer types, their presence unequivocally signals systemic dissemination of the disease. A deep paradox exists wherein the surgical act intended to cure cancer may itself create a biological environment conducive to the growth and spread of residual disease [145]. First, while surgery aims to physically eradicate a localized tumor, cancer at diagnosis is often already a systemic disease with disseminated, dormant micro metastases beyond the reach of the scalpel [146]. Second, the surgical procedure itself is a significant biological stressor [147]. Manipulation and resection of the tumor can inevitably lead to the shedding of a large number of cancer cells into the bloodstream and lymphatic circulation; some studies show that the number of circulating tumor cells (CTCs) can increase more than tenfold. The level of intraoperative CTCs has been shown to be a potent predictor of recurrence [[148], [149], [150]]. Concurrently, the perioperative period is marked by a suppression of the body's anti-tumor immune function, creating a window of opportunity for these newly released CTCs to survive and implant [151]. Finally, surgical trauma triggers both local and systemic inflammatory responses. This inflammatory milieu can “awaken” dormant micro metastases and promote the capture, implantation, and growth of CTCs in distant organs through mechanisms including the release of catecholamines and prostaglandins, and the formation of neutrophil extracellular traps. Radiotherapy and chemotherapy The advent of radiotherapy and chemotherapy expanded cancer treatment from purely local excision to regional and systemic assault [[152], [153], [154]]. The core principle of radiotherapy is to induce irreparable DNA damage in tumor cells either directly or indirectly thereby triggering cell death. The primary bottleneck of conventional radiotherapy was the “collateral damage” inflicted upon normal tissues along the beam path as it traversed the body to reach the tumor. To overcome this, modern radiotherapy has undergone a technological revolution. Intensity-Modulated Radiation Therapy finely adjusts the intensity of radiation beams to conform the high-dose region precisely to the shape of the tumor while dramatically reducing the dose to surrounding critical organs. Stereotactic Body Radiation Therapy delivers an extremely high, ablative dose of radiation to a well-defined, small tumor in just a few treatment sessions [[155], [156], [157]]. Proton and heavy-ion therapy leverage the unique physical property of charged particles known as the “Bragg peak,” where they deposit the majority of their energy at a specific depth corresponding to the tumor location, after which the dose rapidly falls to near zero. This achieves an ideal dose distribution with minimal to no damage to tissues behind the tumor [158]. These technological leaps have vastly improved the “therapeutic ratio” of radiotherapy enhancing tumor control while significantly reducing toxicity. Chemotherapeutic agents kill tumor cells by interfering with various phases of the cell cycle [141]. Their mechanisms can be broadly classified: alkylating agents form cross-links with DNA to prevent its replication; antimetabolites mimic normal metabolites to be fraudulently incorporated into DNA/RNA or inhibit key enzymes; topoisomerase inhibitors prevent the unwinding and replication of DNA; and microtubule inhibitors “freeze” the mitotic spindle required for cell division. This indiscriminate attack on cellular proliferation is the source of both their broad-spectrum anticancer activity and their significant toxicity. Targeted and immunotherapy Targeted therapy is a precision-strike approach based on the concept of “oncogene addiction,” where a tumor is dependent on a specific driver gene [159]. Its success stories are numerous: imatinib targets the BCR-ABL fusion gene, transforming chronic myeloid leukemia into a manageable chronic disease; vemurafenib targets the BRAF V600E mutation, achieving breakthroughs in melanoma; and osimertinib targets the EGFR T790M resistance mutation in NSCLC, overcoming acquired resistance [160]. The mechanism of ICIs is to block the signaling pathways that tumors use to “disguise” themselves and “paralyze” the immune system [[161], [162], [163]]. Tumor cells often overexpress PD-L1, which binds to the PD-1 receptor on T cells, delivering a “do not attack” inhibitory signal. PD-1/PD-L1 inhibitors sever this connection, restoring the T cells' cytotoxic function. Another key checkpoint, CTLA-4, acts as an inhibitory brake at an earlier stage of T-cell activation. CTLA-4 inhibitors “release” this initial brake to broaden and intensify the immune response. The limitations of immunotherapy are, first and foremost, the heterogeneity of response among patients [164]. This is closely linked to the tumor's “immune phenotype.” Generally, patients with “hot tumors” those with high T-cell infiltration and a high tumor mutational burden have higher response rates [[165], [166], [167], [168]]. In contrast, “cold tumors,” which are devoid of immune cell infiltration, are often unresponsive. A major frontier in current research is developing strategies to convert “cold” tumors into “hot” ones. Second, their unique spectrum of irAEs poses a significant challenge to clinical management [169]. Because the immune system is activated non-specifically, it can attack any organ, leading to pneumonitis, colitis, hepatitis, endocrinopathies, and even myocarditis, which can be life-threatening in severe cases. Nanozyme-based therapeutic strategies for lung cancer Nanozymes are engineered nanomaterials possessing intrinsic enzyme-like catalytic activities that can convert endogenous or exogenous substrates into therapeutically active species under physiological or pathological conditions [[170], [171], [172]]. Compared with natural enzymes, nanozymes exhibit superior physicochemical stability, tunable catalytic activity, scalable synthesis, and versatile surface functionalization capabilities [173]. These features have enabled the rapid development of nanozyme-based therapeutic systems for cancer treatment [174]. Although many current nanozyme systems are described as “precision” therapeutic platforms, most designs primarily respond to broad tumor microenvironment characteristics shared across multiple solid tumors, including hypoxia, elevated H2O2 levels, mild acidity, glutathione overexpression, and redox imbalance [[175], [176], [177]]. Consequently, truly genotype-specific catalytic nanomedicine remains relatively underdeveloped [[178], [179], [180], [181]]. In lung cancer, distinct driver mutations not only activate different oncogenic signaling pathways but also shape unique metabolic and immune phenotypes that may influence responsiveness to nanozyme-based therapy. For example, EGFR-mutant tumors frequently exhibit enhanced antioxidant capacity, low tumor mutational burden, sparse immune-cell infiltration, and resistance to immune checkpoint blockade, suggesting that nanozyme systems capable of inducing immunogenic cell death, amplifying ROS stress, or remodeling immunosuppressive tumor microenvironments may provide therapeutic benefit. In contrast, KRAS-driven tumors often display increased metabolic plasticity, inflammatory signaling, and oxidative stress dependence, potentially rendering them more susceptible to ferroptosis-oriented catalytic therapy, glutathione depletion, or metabolic disruption strategies. However, despite these biologically distinct contexts, most currently reported nanozyme platforms are not specifically designed according to molecular subtype-associated vulnerabilities. Instead, they largely function as broad-spectrum catalytic amplifiers targeting generalized tumor redox imbalance. Therefore, integrating genomic profiling, metabolic dependency analysis, and mutation-associated immune phenotypes into nanozyme design may represent an important future direction for achieving genuinely precise catalytic nanomedicine in lung cancer. In lung cancer, nanozymes are particularly attractive because they can exploit hallmark features of the TME, including hypoxia, acidic pH, elevated H2O2 levels, glutathione overexpression, metabolic dysregulation, and immunosuppressive signaling. Through catalytic ROS generation, oxygen modulation, cascade reactions, and metabolic intervention, nanozymes can sensitize tumors to chemotherapy, radiotherapy, phototherapy, and immunotherapy [[182], [183], [184]]. However, current nanozyme systems exhibit substantial heterogeneity in material composition, catalytic efficiency, biosafety, biodegradability, and translational potential [[185], [186], [187]]. Therefore, rather than simply categorizing studies according to therapeutic modality [[188], [189], [190]], it is important to systematically compare the structural characteristics, catalytic mechanisms, and biological behaviors of different nanozyme platforms [191,192]. Their activity can be finely tuned by modulating their elemental composition, valence states, crystal defects, size, morphology, and surface ligands. They typically exhibit greater tolerance to harsh conditions, maintaining activity over broader temperature and pH ranges [[193], [194], [195]]. Furthermore, their surfaces are readily functionalized with drugs, prodrugs, nucleic acids, or peptides, enabling theranostic integration and multi-modal synergy [[196], [197], [198]]. Common material systems include metals and alloys, metal oxides and sulfides, Prussian blue and its analogues, MOFs, doped carbon materials, 2D materials, and single-atom catalytic systems. Their catalytic kinetics can often be described by the Michaelis-Menten model, with substrate affinity and maximum reaction velocity being engineered to match the specific conditions of the TME [[199], [200], [201]]. Table 3 summarizes the characteristics and advantages of different nanozymes. Table 3Advantages and characteristics of different types of nanozymes.Table 3Nanozyme platformRepresentative materialsMajor catalytic activityKey advantagesMain limitationsPotential translational concernsMetal/metal oxide nanozymesFe3O4, MnO2, CuO, CeO2POD-like, CAT-like, Fenton/Fenton-like catalysisStrong ROS generation, simple synthesis, high catalytic activityDependence on acidic pH or endogenous H2O2, off-target oxidative damageLong-term metal accumulation and biosafety concernsNoble metal nanozymesPt, Au, Pd nanoparticlesPOD/CAT-like catalysis, photothermal enhancementHigh catalytic efficiency and photothermal performanceHigh cost and relatively poor biodegradabilitySlow clearance and manufacturing costMOF-based nanozymesFe-MOF, Cu-MOF, ZIF-based systemsCascade catalysis, multifunctional catalytic integrationHigh porosity, tunable structure, efficient drug loadingStructural instability in physiological conditionsUncertain degradation products and in vivo stabilitySingle-atom nanozymes (SACs)Fe–N–C, Cu–N–C systemsHighly selective enzyme-mimicking catalysisMaximized atomic utilization and high catalytic specificityComplex synthesis and limited large-scale reproducibilityScale-up difficulty and characterization challengesCarbon-based nanozymesGraphene oxide, carbon dotsROS modulation and photothermal-assisted catalysisGood biocompatibility and surface modifiabilityLower intrinsic catalytic activityCatalytic efficiency optimization requiredMXene-based nanozymesTi3C2Tx and related MXenesPhotothermal/catalytic synergistic activityExcellent photothermal conversion and multimodal integrationSurface oxidation and stability issuesLong-term biosafety remains unclearHybrid composite nanozymesMOF-metal hybrids, polymer compositesMultifunctional cascade catalysisIntegrated therapeutic functions and enhanced synergyIncreased structural complexityDifficult quality control and manufacturing standardization Advantages and characteristics of different types of nanozymes. Classification and catalytic characteristics of nanozymes Nanozymes used in lung cancer therapy can be broadly categorized into several major classes, including metal/metal oxide nanozymes, noble metal nanozymes [[202], [203], [204], [205]], MOF-based nanozymes, carbon-based nanozymes, MXene nanozymes, and single-atom catalytic systems [206]. These material platforms differ substantially in catalytic mechanism, substrate preference, biocompatibility, structural programmability, and in vivo translational potential [207]. Metal and metal oxide nanozymes, represented by Fe3O4, MnO2, CuO, and CeO2 systems [208], are among the earliest and most extensively investigated nanozyme platforms. These materials commonly exhibit peroxidase-like (POD-like), catalase-like (CAT-like), superoxide dismutase-like (SOD-like), or glutathione peroxidase-like (GPX-like) activities [209]. Their catalytic behavior is often highly dependent on pH and substrate availability, making them particularly suitable for exploiting the acidic and H2O2-rich lung tumor microenvironment. Iron- and copper-based systems can additionally induce ferroptosis or cuproptosis through lipid peroxidation and glutathione depletion [210]. However, concerns remain regarding long-term metal accumulation, off-target oxidative damage, and biodegradation kinetics. Noble metal nanozymes, including Pt-, Au-, and Pd-based systems, generally exhibit high catalytic efficiency and excellent photothermal stability [[211], [212], [213]]. Due to their strong near-infrared absorption properties, they are frequently integrated with photothermal or photodynamic therapy. Nevertheless, the high manufacturing cost and relatively slow in vivo clearance of noble metal systems may limit large-scale clinical translation. MOF-based nanozymes have emerged as highly versatile catalytic platforms because of their tunable porosity, large surface area, and capacity for drug or enzyme loading. Their porous architecture facilitates cascade catalytic reactions and substrate enrichment, enabling synergistic therapeutic strategies that combine glucose depletion, ROS amplification, oxygen generation, and controlled drug release. In particular, MOFs can spatially confine catalytic centers, thereby improving substrate accessibility and reaction efficiency. Despite these advantages, MOF systems may suffer from insufficient structural stability in biological fluids and require further investigation regarding degradation products and long-term biosafety. Single-atom nanozymes represent a rapidly developing frontier in catalytic nanomedicine. By atomically dispersing catalytic metal centers within carbon or coordination frameworks, these systems maximize atomic utilization efficiency and can more precisely mimic the catalytic microenvironment of natural enzymes. Compared with conventional metal oxide nanozymes, single-atom catalysts often demonstrate improved catalytic selectivity and enhanced reaction kinetics under physiological conditions. However, challenges associated with scalable synthesis, structural characterization, and manufacturing reproducibility remain significant barriers to clinical translation. Carbon-based nanozymes and MXene systems possess favorable biocompatibility, tunable surface chemistry, and intrinsic optical properties. Through heteroatom doping, defect engineering, or hybridization with metallic components, these materials can achieve multifunctional catalytic activities while simultaneously serving as photothermal or imaging agents. MXene nanozymes, in particular, have attracted increasing attention because of their excellent photothermal conversion efficiency and multimodal therapeutic potential. Nonetheless, the catalytic efficiency of carbon-based systems often remains lower than that of metal-containing nanozymes, necessitating further optimization of active sites and electronic structures. Collectively, these nanozyme platforms illustrate that catalytic performance alone is insufficient for evaluating therapeutic potential. Instead, future lung cancer nanozyme systems must balance catalytic efficiency, substrate dependence, biosafety, biodegradability, pulmonary delivery compatibility, and clinical manufacturability to achieve successful translation. Catalytic sensitization and chemotherapy Nanozymes enhance local therapeutic potency without increasing systemic exposure by catalytically repurposing endogenous substrates within the TME, such as H2O2, dissolved oxygen, and GSH, into highly reactive species or by depleting critical antioxidant factors [214]. Key strategies include the amplification of •OH via peroxidase-like (POD-like) or Fenton-like reactions; the attenuation of the cellular redox buffering capacity via glutathione peroxidase-like (GPX-like) or oxidase-like (OXD-like) activity; and the triggering of lipid peroxidation to induce ferroptosis and cuproptosis using iron- and copper-based systems [[215], [216], [217]]. Furthermore, cascaded reactions with modules like GOx can achieve simultaneous substrate self-supply and starvation therapy. Nanozymes also serve as hubs for prodrug activation and pharmacokinetic redistribution, enabling the selective release of cytotoxic agents in the acidic or hypoxic TME and coupling their effects with radical-based chemistry. This approach aims to overcome the therapeutic ceiling imposed by stromal barriers, hypoxic adaptation, and drug resistance networks. Compared with conventional ROS-amplifying nanozymes that primarily rely on a single cell death pathway, recent catalytic systems increasingly attempt to induce multiple forms of programmed cell death simultaneously to overcome therapeutic resistance in lung cancer. A representative example is the two-dimensional calcium manganese oxide nanosheet (CMO NS) platform reported by Wang et al. [218], which integrated ferroptosis, mitochondrial dysfunction, and apoptosis through a cascade catalytic strategy combined with ultrasound-enhanced activation. Mechanistically, the CMO nanosheets exhibited multiple enzyme-mimetic activities, including POD-like, OXD-like, GPX-like, and GOx-like catalytic behavior. This multifunctional catalytic profile enabled simultaneous glucose depletion, H2O2 generation, ROS amplification, and glutathione disruption, thereby coupling metabolic stress with oxidative injury. In addition, Mn valence cycling continuously promoted ROS production, while Ca2+ release contributed to intracellular calcium overload and mitochondrial dysfunction. Such cooperative regulation of redox stress and calcium homeostasis allowed the system to trigger both ferroptosis and apoptosis rather than relying on a single cytotoxic mechanism. Importantly, this study also highlighted the growing role of external energy-assisted catalytic amplification in nanozyme therapy. Under ultrasound stimulation, ROS generation was significantly enhanced, suggesting that physical energy input may help overcome the insufficient catalytic efficiency often observed under physiological conditions. Compared with traditional metal oxide nanozymes that depend solely on endogenous tumor microenvironment activation, externally enhanced catalytic systems may provide more robust ROS amplification and therapeutic efficacy in heterogeneous tumors. However, this strategy may also increase treatment complexity and dependence on local energy penetration. In vitro and in vivo experiments demonstrated substantial tumor suppression accompanied by increased lipid peroxidation, glutathione depletion, GPX4 downregulation, ACSL4 upregulation, mitochondrial dysfunction, and apoptosis activation. Notably, the therapeutic performance of the CMO nanosheets exceeded that of conventional Fe3O4 nanozymes, supporting the potential advantage of integrating multi-enzyme catalytic activity with external ultrasound-assisted activation. Overall, this work illustrates an important emerging design principle in catalytic nanomedicine: rather than maximizing ROS production alone, next-generation nanozyme systems increasingly integrate metabolic disruption, ion homeostasis dysregulation, and multimodal cell death induction to overcome adaptive resistance in lung cancer. Nevertheless, the long-term biosafety, catalytic stability, and translational feasibility of such externally enhanced multifunctional systems still require further validation (Fig. 4). (A) Schematic representation of the antitumor functionality of CMO nanostructures. These nanostructures possess multiple enzyme-mimetic activities and exert antitumor effects through two key pathways: ferroptosis and calcium overload-induced apoptosis. When combined with exogenous ultrasound, the release of CMO ions and the rate of catalytic reactions are accelerated, ultimately achieving efficient enzyme-kinetically driven synergistic therapy through the combined effects of ferroptosis and apoptosis. (B) Bio-transmission electron microscopy images showing M109 cells treated with ultrasound-induced CMO, in comparison with the control group. Yellow arrows indicate mitochondria that have undergone damage. (C) Schematic diagram illustrating the lipid peroxidation process. Copyright from Ref. [218]. Wiley-VCH 2024. To overcome the limitations of substrate insufficiency and antioxidant adaptation in catalytic therapy, recent nanozyme systems increasingly integrate metabolic intervention, cascade catalysis, and externally enhanced activation into multifunctional therapeutic platforms. A representative example is the Cu2O@Au nanozyme system reported by Li et al. [219], which combined GOx-like, POD-like, and GPX-like activities to disrupt tumor energy metabolism and redox homeostasis simultaneously. Mechanistically, Au nanoparticles endowed the system with GOx-like catalytic activity, enabling glucose consumption and continuous H2O2 generation within the tumor microenvironment. This process not only induced starvation-like metabolic stress but also supplied substrates for downstream Fenton-like catalytic reactions mediated by Cu valence cycling. Meanwhile, glutathione depletion and inhibition of GPX4/xCT antioxidant pathways further amplified lipid peroxidation and ferroptosis sensitivity. Such integration of metabolic disruption, ROS amplification, and antioxidant suppression illustrates an emerging trend in catalytic nanomedicine toward coordinated regulation of multiple tumor survival pathways rather than relying solely on direct ROS production. Compared with conventional ROS-generating nanozymes, this multifunctional cascade strategy may partially overcome one of the major limitations of catalytic therapy, namely insufficient endogenous H2O2 availability. In addition, the incorporation of photothermal enhancement further improved catalytic efficiency under physiologically mild conditions. Local hyperthermia accelerated catalytic reactions and increased oxidative stress, suggesting that external energy-assisted catalysis may help compensate for heterogeneous tumor microenvironments where endogenous catalytic activation alone is insufficient. However, such strategies also increase system complexity and dependence on external irradiation conditions. Both in vitro and in vivo experiments demonstrated strong tumor suppression accompanied by glutathione depletion, GPX4 downregulation, lipid peroxidation, and activation of ferroptotic and apoptotic pathways. Importantly, the system also showed selective cytotoxicity toward tumor cells while exhibiting relatively favorable biosafety in normal tissues. These findings support the concept that coupling catalytic therapy with metabolic remodeling and photothermal enhancement may provide a more robust strategy for overcoming redox adaptation and therapeutic resistance in lung cancer. Overall, this work highlights an important design principle for next-generation nanozymes: multifunctional catalytic systems capable of simultaneously modulating energy metabolism, redox homeostasis, and cell death pathways may achieve superior therapeutic efficacy compared with single-mechanism catalytic platforms. Nevertheless, the long-term biosafety, catalytic stability, and translational feasibility of such highly integrated systems remain important challenges for future clinical application (Fig. 5). Schematic diagram of the preparation of Cu2O@Au-based nanozymes and the anti-tumor mechanism through photothermal therapy. Copyright from Ref. [219]. ACS 2024. Nanozyme-enhanced photothermal and photodynamic therapy PTT enables spatiotemporally programmable hyperthermia within the lesion [220]. In turn, the elevated temperature can accelerate reaction kinetics, diffusion, and interfacial catalysis, thereby creating a positive feedback loop wherein the energy input promotes catalysis, and the catalytic products enhance the photothermal effect [221]. By constructing switchable photothermal systems that are sensitive to acidity, hydrogen peroxide, or reaction intermediates, heating can be confined to the TME, reducing the risk of overheating normal tissues. This localized heating can also improve microcirculation and oxygen supply, thereby enhancing the responsiveness to photodynamic therapy and radiotherapy. Within this framework, nanozymes serve a dual role, acting as both photothermal agents and as catalysts that improve the efficiency of thermal and light-induced cell death through mechanisms such as oxygen generation, reductant depletion, and prodrug activation. The following section reviews the progress and key challenges of this strategy in lung cancer, focusing on the material's optical parameters and thermal response thresholds, reaction-triggering modes and dose modulation, engineering considerations for intravenous versus pulmonary delivery, and image-guided closed-loop control. Wu et al. [222]. Proposed a two-dimensional vanadium carbide MXene (V2C MXenzyme) that integrates photothermal effects with multi-enzyme-like activities, offering a new strategy for lung cancer PTT. The core concept of this design is to leverage the high near-infrared (NIR) absorption efficiency and intrinsic enzyme-mimicking catalytic activities of V2C nanosheets to achieve a dual function of “photothermal ablation” and “anti-inflammatory protection,” thereby mitigating the inflammatory side effects commonly associated with PTT. In terms of material properties, the V2C MXenzyme demonstrated excellent photothermal conversion efficiency. Upon irradiation with an 808 nm laser, the temperature of a 300 μg/mL solution rapidly increased to approximately 60 °C within 10 min, a level that can be stably maintained at the threshold required for tumor ablation. The material also retained stable heating performance over multiple heating-cooling cycles. Furthermore, the V2C MXenzyme exhibited multiple enzyme-like activities, including those of SOD, CAT, POD, and GPX, enabling it to effectively scavenge ROS. In vitro, the V2C MXenzyme, under NIR irradiation, significantly induced apoptosis and necrosis in A549 lung cancer cells, with cell viability dropping below 20%. In contrast, normal fibroblast cells maintained high viability under the same conditions because the oxidative stress was effectively mitigated. Concurrently, the levels of inflammatory cytokines IL-6 and TNF-α secreted by macrophages were reduced by approximately 50% and 60%, respectively, showcasing the material's anti-inflammatory potential. In vivo, a mouse xenograft model of lung cancer was treated with injected V2C MXenzyme followed by NIR irradiation, leading to a rapid increase in tumor temperature to 55–60 °C within 5 min. Compared to the control groups, tumors in the treatment group were almost completely eradicated within 14 days, with a tumor inhibition rate exceeding 95%; some animals even achieved complete tumor elimination. Serological tests showed a significant decrease in inflammatory cytokine levels, and histological analysis revealed no damage to major organs such as the heart, liver, spleen, lungs, and kidneys. Transcriptomic analysis further revealed that the expression of inflammation-related genes, such as HSPA1A, was downregulated. This gene was also found to be associated with immune cell infiltration and prognosis in lung adenocarcinoma, suggesting a potential immunomodulatory role. Overall, this study puts forward a dual-function strategy that achieves both photothermal therapy and anti-inflammatory regulation via an MXene-based nanozyme. It not only demonstrated near-complete tumor elimination in an animal model but also provided evidence at the molecular and immunological levels for the significant alleviation of inflammatory side effects. This work offers a solution to the dilemma of co-existing efficacy and inflammation in PTT and provides important insights for future combination applications in precision lung cancer therapy, such as integration with radiotherapy or immunotherapy (Fig. 6). (A) Schematic diagram illustrating the preparation process of unilayered V2CTx. (B) Schematic diagram demonstrating the fabrication procedure of unilayered V2C MXenzyme. (C) The application of V2C MXenzyme in lung cancer therapy: leveraging photothermal properties to achieve targeted inhibition of lung tumors and elimination of inflammatory responses. Copyright from Ref. [222]. Wiley-VCH 2024. Cai et al. [223]. developed a “cascade reaction-type nanozyme platform” based on RuTe2 nanorods (RGT NRs) that achieves multi-modal synergistic therapy against lung cancer by integrating peroxidase-mimicking activity, glucose consumption, and a photothermal effect (Fig. 7). The design concept involved co-loading GOx and the chromogenic substrate TMB onto RuTe2 nanorods to form an all-in-one catalytic and theranostic composite. GOx catalyzes glucose to produce H2O2, providing a continuous supply of substrate for the POD-like activity of the RuTe2 nanorods, which in turn efficiently generate •OH radicals in the acidic TME. Simultaneously, the TMB is oxidized to oxTMB, a species with strong NIR absorption properties. This achieves a “reaction-activated” photothermal effect, thereby avoiding the non-specific heating associated with conventional photothermal agents. Thus, the platform elevates antitumor efficacy through a threefold attack: starvation therapy, CDT, via •OH generation, and tumor-specific PTT. In vitro, RGT NRs generated a large amount of ROS under pH 6.0 conditions, as confirmed by a significant increase in the signal from a fluorescent probe; cell viability was restored upon the addition of an antioxidant, confirming the dominant role of free radicals in cell death. When applied to A549 lung cancer cells, RGT NRs under laser irradiation (808 nm, 1.5 W/cm2, 5 min) reduced cell viability to below 20% and significantly increased apoptosis levels. This effect was limited under neutral pH or in the absence of glucose, demonstrating excellent tumor specificity. In vivo, tumor-bearing mice intravenously injected with RGT NRs and subjected to laser irradiation exhibited a rapid increase in local tumor temperature to 53 °C, and the primary tumors were almost completely eliminated after 15 days of treatment. More notably, the system induced potent ICD: ATP secretion increased 5.1-fold, and cell surface exposure of calreticulin (CRT) and release of HMGB1 were significantly enhanced. This promoted the maturation of dendritic cells and activated the infiltration of CD4+ and CD8+ T cells. In a lung metastasis model, mice showed a significant reduction in metastatic nodules, with some individuals exhibiting a complete absence of lung metastases. This indicates that the system not only eradicated the primary tumor but also triggered a systemic immune effect to inhibit distant metastasis. Hematological and histological analyses revealed no significant toxicity in major organs, further proving its biosafety. Illustration of the preparation of RGT NRs and sequential catalytic-therapeutic mechanism on the generation of hydroxyl radicals for synergetic cancer therapy. Copyright from Ref. [223]. Wiley-VCH 2023. Immunotherapy This section, framed from the perspective of integrated immunomodulation, elucidates how nanozymes can establish a higher response baseline for checkpoint inhibition and effector immune responses [224]. Through programmable ROS and metal ion signaling, nanozymes can induce ICD, promoting antigen release and exposure, enhancing dendritic cell (DC) maturation and cross-presentation, and consequently increasing the quantity and efficacy of tumor-infiltrating T cells. Concurrently, nanozymes can alleviate hypoxia and acidosis, suppress immunosuppressive cell populations, and repolarize tumor-associated macrophages (TAMs) toward a pro-inflammatory phenotype. In specific designs, they can also enhance the sensitivity of tumor cells to checkpoint blockade through metabolic reprogramming and membrane receptor modulation, thereby driving the transition from an immunologically “cold” to a “hot” state. The following discussion, supported by mechanistic evidence and animal model data, will explore key aspects such as dose and timing orchestration, the interplay between local and systemic immunity, and the controllable boundaries of immune-related adverse events. Beyond conventional tumor microenvironment-responsive catalytic systems, recent studies have begun exploring physiologically driven nanozyme strategies that utilize endogenous mechanical or biochemical signals for sustained catalytic activation. A representative example is the piezocatalytic nanozyme platform (O3P@LPYU) reported by Xu et al. [225] for the treatment of malignant pleural effusion (MPE), a severe complication frequently associated with advanced lung cancer. This system was designed to exploit the unique physiological characteristics of the thoracic cavity, particularly continuous respiratory pressure fluctuations and local oxygen availability. By incorporating Yb-doped UiO-66 within a liposomal structure co-loaded with ozone, the nanozyme could convert mechanical stimulation generated during respiration into catalytic ROS production through a piezoelectric effect. Compared with conventional externally activated catalytic systems, this strategy avoided dependence on external irradiation equipment and enabled continuous self-activating ROS generation within the pleural environment. Mechanistically, piezocatalytic activation promoted the generation of multiple ROS species and induced substantial oxidative stress in tumor cells. Importantly, the catalytic process was also associated with ICD, as evidenced by enhanced danger-associated molecular signal release and subsequent activation of anti-tumor immunity. In addition to direct tumor suppression, the system significantly reduced inflammatory cytokine secretion associated with pleural effusion progression, suggesting that catalytic therapy may simultaneously regulate both tumor burden and pathological inflammatory microenvironments. In vivo studies demonstrated effective suppression of pleural metastasis, reduction of malignant pleural effusion recurrence, and prolonged survival. Immunological analyses further revealed increased infiltration of CD8+ T cells and dendritic cells accompanied by reduced immunosuppressive cell populations, indicating successful remodeling of the pleural immune microenvironment. These findings highlight the growing importance of combining catalytic therapy with immune activation strategies in advanced lung cancer treatment. More importantly, this work introduces an emerging design principle for next-generation nanozymes: rather than relying solely on chemical triggers such as acidity or elevated H2O2, catalytic systems may increasingly integrate endogenous physiological signals, including mechanical stimulation, respiratory dynamics, or local bioelectrical environments, to achieve sustained and spatially localized activation. Such physiologically responsive catalytic platforms may be particularly valuable for lung-associated diseases because the respiratory system naturally provides dynamic mechanical cues that can potentially be harnessed for therapeutic activation. Nevertheless, several translational challenges remain unresolved, including long-term pleural retention, piezocatalytic stability under physiological conditions, and the biosafety of prolonged ROS generation within sensitive pulmonary tissues. Further investigation will therefore be necessary before clinical application (Fig. 8). (A) Schematic illustration of the synthesis of O3P@LPYU NPs and their application in piezocatalytic therapy responsive to IPP. (B) The therapeutic regimen for O3P@LPYU-based piezocatalytic therapy. (C) Bioluminescence images and (D) ultrasound images of LLC-MPE mice from different treatment groups, acquired every other day after the initiation of treatment. Copyright from Ref. [225]. Springer 2025. Xu et al. [226]. Proposed an intelligent biomimetic nanodrug (CMGCL) that effectively enhances αPD-L1 immunotherapy in lung cancer through a dual metabolic intervention combining glucose starvation with cuproptosis. The system consists of a core made of copper-doped layered double hydroxides (Cu-LDHs) loaded with GOx, which is then camouflaged with a lung cancer cell membrane to confer homologous targeting capabilities. The design rationale is to use GOx to deplete glucose, thereby inducing a starvation effect and generating H2O2. Simultaneously, the copper ions participate in glutathione depletion and Fenton-like reactions, further inducing mitochondrial damage and cuproptosis, thus achieving a multi-catalytic amplification. Critically, the combined stress of glucose deprivation and copper dyshomeostasis was found to significantly upregulate PD-L1 expression on tumor cells, creating a favorable condition for combination therapy with αPD-L1. In vitro, CMGCL at a concentration of 4 μg/mL reduced the viability of LLC lung cancer cells to below 50% and induced an apoptosis rate of 74.1%, which was significantly higher than the uncoated or unloaded control groups (apoptosis rates of 17.8% and 67.2%, respectively). Further analysis showed that intracellular GSH levels dropped by over 60% after treatment, accompanied by a loss of mitochondrial membrane potential and an upregulation of Bax and downregulation of Bcl-2. Key molecules in the cuproptosis pathway, FDX1 and LIAS, were significantly downregulated, while the oligomerization of DLAT was enhanced, validating the occurrence of copper-dependent cell death. Concurrently, flow cytometry revealed a significant upregulation of PD-L1 expression by approximately 2-fold compared to the control group, providing a basis for sensitization to immune checkpoint therapy. In in vivo mouse experiments, CMGCL monotherapy achieved a tumor inhibition rate of 66.4%, which was superior to the uncoated Cu-LDHs (51.3%). When combined with an αPD-L1 antibody, the therapeutic effect was further potentiated, with tumor weight decreasing by over 60%. In a lung metastasis model, the number of metastatic nodules was reduced to an average of 3.4, which was only 15% of that in the control group. Immunohistochemical analysis showed that the CMGCL plus αPD-L1 combination significantly increased the infiltration of CD8+ T cells and NK cells by 2.6-fold and 2.1-fold, respectively, compared to the control group, while PD-L1 expression was markedly enhanced throughout the tumor cell population. In terms of safety, no significant toxic changes were observed in the major organs of the mice, and serological markers remained within the normal range (Fig. 9). Schematic diagram of the synergistic effects of CMGCL-induced glucose starvation and goblet apoptosis on sensitivity to αPD-L1 therapy in lung cancer. Copyright from Ref. [226]. Wiley-VCH 2024. Multimodal nanozyme-based synergistic therapy Monotherapies are often inadequate to address the complex pathological environment and multifaceted characteristics of lung cancer [227]. The modular integration of catalytic, photothermal, photodynamic, and metabolic interventions with standard-of-care treatments represents an effective strategy to break through the efficacy ceiling of single-pathway approaches [228]. An ideal platform would be triggered by signals from the lesion itself, incorporating logic-gated and temporally controlled activation to enable a sequential synergy designed to “first remodel the microenvironment, then amplify the primary therapeutic effect, and subsequently consolidate immunological memory.” This would be coupled with imaging readouts to create a closed-loop regulatory system, aiming to achieve maximum local and systemic efficacy with minimal systemic exposure [229]. The design and evaluation of such platforms must encompass the quantification of synergistic gain, the compatibility windows of different triggers, the adaptability of delivery routes, and critical quality attributes and manufacturability. Recent nanozyme strategies have increasingly shifted from single catalytic amplification toward integrated immunometabolic regulation and multimodal synergistic therapy. A representative example is the multifunctional AP-HAI nanozyme platform reported by Zhang et al. [230], which combined spatially confined ultrasmall Pt nanozymes with PTT, PDT, mitochondrial respiration inhibition, and immune activation for enhanced lung cancer treatment. This system employed a spatial confinement strategy to generate highly active ultrasmall Pt nanozymes on gold nanobipyramids, thereby improving catalytic accessibility and photothermal responsiveness. Importantly, the incorporation of the mitochondrial respiratory inhibitor atovaquone (ATO) addressed one of the major limitations of photodynamic and catalytic therapies, namely insufficient oxygen availability within tumors. By suppressing mitochondrial oxygen consumption, ATO increased local oxygen retention and consequently enhanced ROS-mediated PDT and catalytic activity. Simultaneously, photothermal heating further promoted the peroxidase-like catalytic performance of the Pt nanozymes, illustrating the growing importance of externally enhanced catalytic amplification in multifunctional nanozyme systems. Compared with conventional catalytic nanozymes that primarily rely on endogenous tumor microenvironment activation, this platform integrated catalytic therapy with metabolic regulation and immune modulation. In addition to strong ROS amplification and tumor suppression, the treatment induced substantial ICD, accompanied by dendritic cell maturation, increased CD8+ T-cell infiltration, and reduced immunosuppressive Treg populations. These findings suggest that catalytic nanomedicine may function not only as a direct cytotoxic strategy but also as a regulator of anti-tumor immunity. Importantly, this work highlights several emerging design principles for next-generation nanozymes. First, spatial confinement engineering may improve catalytic efficiency by optimizing active-site exposure and nanoscale reaction environments. Second, metabolic intervention strategies such as mitochondrial respiration inhibition can help overcome oxygen limitations that frequently restrict PDT and catalytic ROS generation. Third, combining catalytic therapy with immune activation may provide a more durable anti-tumor response compared with ROS amplification alone. Nevertheless, the increasing structural complexity of multifunctional nanozyme systems also introduces translational challenges, including manufacturing reproducibility, long-term biosafety, catalytic stability in physiological environments, and difficulties in standardized clinical evaluation. Therefore, balancing multifunctionality with translational simplicity remains an important challenge for future nanozyme development (Fig. 10). Schematic diagram of combined therapy-based lung cancer treatment. (A) Systematic fabrication process of AP-HAI nanoprobes. (B) In vivo therapeutic mechanism of AP-HAI nanoprobes. Copyright from Ref. [230]. Wiley-VCH 2023. Beyond conventional ROS-based catalytic therapy, recent nanozyme designs have increasingly explored the integration of catalytic immunomodulation and gas signaling regulation to achieve more comprehensive tumor microenvironment remodeling. A representative example is the chiral ruthenium nanozyme system reported by Chen et al. [231], which combined oxidase-like and nitric oxide synthase-like catalytic activities within a single platform to simultaneously induce oxidative stress and nitric oxide (NO)-mediated immune activation. Mechanistically, the nanozyme utilized endogenous H2O2 to generate ROS and oxygen while subsequently catalyzing in situ NO production from arginine ligands. The synergistic interaction between ROS and NO not only promoted direct tumor cytotoxicity but also facilitated macrophage repolarization toward a pro-inflammatory M1 phenotype, thereby enhancing anti-tumor immune responses. Compared with traditional catalytic systems that primarily rely on ROS amplification alone, this dual-signaling strategy highlights the growing importance of integrating redox regulation with immune modulation in catalytic nanomedicine. Importantly, this study also demonstrated the potential significance of chirality in nanozyme design. The L-Arginine@Ru configuration exhibited superior catalytic activity, glutathione depletion capability, intracellular uptake, and immune remodeling effects compared with its D-enantiomer counterpart. These findings suggest that chirality may influence catalytic accessibility, biological interactions, and cellular recognition processes, thereby affecting overall therapeutic performance. Such observations provide a new perspective for the rational design of biomimetic catalytic nanoplatforms. In vitro and in vivo studies demonstrated substantial ROS accumulation, lipid peroxidation, ferroptosis- and apoptosis-related signaling activation, and significant tumor suppression. More importantly, treatment was accompanied by increased infiltration of CD8+ and CD4+ T cells, enhanced M1 macrophage polarization, reduced immunosuppressive cytokine signaling, and suppression of hypoxia-associated pathways. These findings indicate that ROS-NO synergistic catalysis may simultaneously regulate oxidative stress, tumor immunity, and hypoxic microenvironments. Overall, this work highlights an emerging trend in nanozyme research toward multifunctional catalytic immunotherapy systems capable of coordinating redox regulation, gas signaling, and immune remodeling. Compared with conventional ROS-dependent nanozymes, such integrated catalytic platforms may provide broader immunological and microenvironmental modulation capabilities. Nevertheless, the long-term biosafety of NO-associated catalytic systems, the stability of chiral nanozyme structures in vivo, and the complexity of immune responses induced by combined ROS/NO signaling still require further investigation before clinical translation (Fig. 11). (A) Illustration of D/L-Arginine@Ru Nanozyme Synthesis and Its Tumor Cell Inhibitory Mechanism via “Cocktail Therapy. (B) Schematic illustration of the construction and therapeutic intervention process for the LLC tumor-bearing BALB/c mouse model. (C) Variations in body weight of nude mice with LLC tumors across different treatment groups over a 15-day period. (D) Tumor volume measurements following various treatment regimens. (E) Observations of tumor morphology and progression status under different treatment conditions, respectively. (F) Photographs of dissected tumors from the BALB/c mouse model in each treatment group on the 15th day. (G) H&E staining, Ki-67 immunohistochemical staining, and TUNEL apoptosis assay were performed to evaluate the anti-tumor efficacy of different treatments on dissected tumor tissues; scale bar = 100 μm, respectively (n = 5). Copyright from Ref. [231]. Wiley-VCH 2023. Challenges in clinical translation Nanozymes, a class of nanomaterials with intrinsic enzyme-mimicking catalytic activities, have garnered widespread attention in the biomedical field in recent years. Compared to natural enzymes, nanozymes exhibit numerous advantages that have been the core drivers of research enthusiasm, including superior stability in harsh environments, lower production costs, potential for scalable synthesis, and tunable multifunctional properties. To date, over 1200 distinct types of nanozymes have been reported, demonstrating their vast application diversity. In preclinical research, nanozymes have shown immense promise in disease diagnosis and therapy, particularly in oncology, anti-inflammatory applications, and biosensing. However, despite a burgeoning body of laboratory research, the pipeline for their successful translation into clinically approved applications remains exceptionally narrow. This translational chasm between “lab and bedside” stems from a series of complex, interrelated, and formidable challenges. In vivo fate and toxicity Ensuring patient safety is the foremost prerequisite for the clinical translation of nanozymes. The dual identity of nanozymes as both nanomaterials and active catalysts imparts a dynamic and environment-dependent toxicity profile, which constitutes one of the most central challenges to their clinical translation [232]. Acute toxicity studies often underestimate the potential hazards of engineered nanomaterials (ENMs). Sub-chronic exposure studies have revealed that delayed cytotoxicity and inflammatory responses, which may be overlooked in short-term assessments, can manifest after prolonged exposure. For instance, a 90-day study on cerium oxide (CeO2) nanoparticles showed that significant cytotoxicity and inflammation only appeared after 60 to 80 days of continuous exposure, highlighting the risk of long-term cumulative effects. Following intravenous injection, nanozymes, like other nanoparticles, are primarily cleared by the mononuclear phagocyte system, leading to their accumulation in organs such as the liver, spleen, and lungs. This accumulation raises concerns about potential long-term organ damage or immunosuppression, although clinically significant immunosuppression has not been widely reported for non-cytotoxic nanomedicines at therapeutic doses. Furthermore, a major safety concern for many intravenously injected nanomedicines is complement activation-related pseudoallergy (CARPA), an acute adverse immune reaction that can cause symptoms of anaphylactic shock. The surface properties of nanozymes can trigger such reactions and must therefore be given high priority in design and preclinical screening. The therapeutic mechanism of many nanozymes relies on the generation of ROS to kill cancer cells. However, if the nanozymes are not precisely targeted, this same mechanism can cause oxidative stress and DNA damage in healthy cells. For example, studies on CeO2 nanoparticles have revealed their contradictory dual roles as both an antioxidant and a pro-oxidant, with their toxicity being highly dependent on the specific context. This functional dichotomy makes it exceptionally difficult to accurately predict their net biological effect in vivo. Nanozymes are not inert in biological fluids. Their high reactivity means they can undergo biotransformation, leading to structural decomposition and alteration of their physicochemical properties, a process that fundamentally affects their long-term efficacy and safety. A study on a MOF-based Mn@PCN224 nanozyme found that although it rapidly decomposed in biological media, its released active centers retained their catalytic activity. This indicates that not only the nanozyme itself but also the activity and toxicity of its degradation products must be comprehensively evaluated. Biodegradation kinetics are another critical factor, significantly influenced by the nanozyme's core composition, size, and especially its surface coating. A 15-month study of iron oxide nanoparticles showed that their degradation was faster in the liver than in the spleen, and that different surface coatings not only dictated their initial biodistribution but also influenced their long-term retention. To ensure clinical viability, nanozymes must be effectively cleared from the body within a reasonable timeframe. The main clearance pathways include uptake and degradation by the MPS, with their components subsequently entering metabolic cycles, and renal filtration of very small particles or degradation products. Therefore, designing for clearance is one of the key principles for advancing nanozymes toward clinical application. Unlike conventional small-molecule therapeutics, many nanozyme systems are composed of inorganic or hybrid nanomaterials that may undergo slow degradation and prolonged retention in vivo. Although biodegradation is often considered beneficial for therapeutic clearance, the gradual release of transition metal ions such as Fe, Cu, Mn, and Co may also introduce nanozyme-specific toxicological risks. Excessive accumulation of these metal ions in non-target organs, particularly the liver, spleen, kidneys, and lungs, may disturb physiological redox homeostasis and trigger unintended oxidative injury. Biological barriers Even if a nanozyme is inherently safe, it must successfully navigate multiple biological barriers to exert its effect at the right place and at the right time. Upon entering the bloodstream, a nanozyme's surface is immediately adsorbed with various plasma proteins, forming a dynamic “protein corona.” This corona completely alters the nanozyme's original physicochemical properties, conferring upon it a new “biological identity.” The formation of the protein corona directly impacts the nanozyme's circulation time, biodistribution, targeting efficiency, and even its catalytic activity. On one hand, it may mask targeting ligands modified on the nanozyme surface, preventing recognition of lesion cells; on the other hand, it may be recognized as a foreign entity by the immune system, leading to rapid clearance by macrophages and drastically shortening its effective time in the body [233]. The composition and structure of the protein corona are dynamic and vary with an individual's physiological state, and this unpredictability poses a tremendous challenge for the precision design of nanozymes. For diseases in specific organs, the barriers are even more complex. In the case of pulmonary delivery, for instance, nanozymes must first overcome the dense mucus barrier composed of mucins. This barrier acts as a physical sieve and an adhesive trap, capturing the vast majority of foreign particles through steric hindrance and hydrophobic/electrostatic interactions. Studies have shown that only nanoparticles with specific surface modifications that present a neutral charge and strong hydrophilicity can efficiently penetrate the mucus layer to reach the underlying epithelial cells. In cancer therapy, nanozymes must also contend with the unique TME. The TME is characterized by high interstitial fluid pressure, a dense extracellular matrix, an aberrant vascular system, and features like hypoxia and acidity. High interstitial pressure impedes the effective extravasation of nanozymes from blood vessels, while the dense matrix restricts their penetration and diffusion within the tumor tissue. Furthermore, while the acidic and hypoxic state of the TME can be cleverly exploited as a “trigger” to activate certain nanozymes, it may also inhibit the catalytic efficiency of others. This environmental sensitivity demands that nanozyme design be precisely matched to the specific pathological microenvironment. Inter-patient heterogeneity and precision medicine For decades, the central tenet for using nanoparticles in cancer therapy has been the “enhanced permeability and retention (EPR) effect.” This passive targeting mechanism posits that nanoparticles preferentially accumulate in tumor tissue due to leaky tumor vasculature and poor lymphatic drainage. However, while the EPR effect is robust in many preclinical rodent models, it exhibits profound heterogeneity in the clinical setting, often being weak or even absent [234]. This variability exists not only between different patients and tumor types but also within different regions of the same tumor. The over-reliance on this unreliable phenomenon is now recognized as a primary reason why many nanomedicines that performed exceptionally well in animal studies failed in clinical trials. This underscores the urgent need to develop active, predictable targeting mechanisms to replace passive, variable ones. This stark discrepancy between preclinical models and human patients reveals a fidelity crisis in the models used to develop nanomedicines. The majority of nanodrugs are developed and tested in rapidly growing, homogenous subcutaneous tumor models in immunodeficient mice, which are known for their pronounced and uniform EPR effect. In contrast, human tumors are slow-growing, genetically diverse, and exist in immunocompetent hosts, leading to vast differences in vasculature and permeability. Consequently, the criterion for selecting promising nanomedicines—namely, high tumor accumulation in mice is based on a biological phenomenon that is not consistently present in the target patient population. This has led to the systemic selection of candidate drugs that are destined to fail in human trials. Scalable manufacturing and consistency The successful synthesis of a nanozyme formulation in the laboratory is merely the first step of a long journey. Scaling up production from milligram-scale “handicrafts” to kilogram-scale “industrial products” that comply with Good Manufacturing Practice (GMP) is a formidable engineering challenge. Synthesis methods that are effective in a research lab, such as thermal decomposition or complex multi-step reactions, often become difficult, expensive, and low-yield when scaled up for industrial production. While methods like co-precipitation are more amenable to scale-up, they typically produce particles with lower crystallinity and higher polydispersity. The properties of a nanozyme size, morphology, surface charge, catalytic activity are extremely sensitive determinants of its biological effects. In small-batch lab synthesis, researchers can precisely control various reaction parameters. However, in large-scale production, issues like mass transfer, heat transfer, and mixing uniformity within the reactor are dramatically amplified. Any minor process fluctuation can lead to significant batch-to-batch variability in Critical Quality Attributes. This inconsistency not only compromises the reliability of the therapeutic effect but is also entirely unacceptable to regulatory agencies. Currently, the development of robust, scalable, and cost-effective GMP manufacturing processes for nanozymes is one of the core technical bottlenecks impeding their industrialization. Unlike structurally well-defined small-molecule drugs, a nanozyme is a complex system whose characterization requires a suite of advanced analytical techniques, including transmission electron microscopy, dynamic light scattering, and high-performance liquid chromatography, to comprehensively assess its physical, chemical, and biological properties. At present, the industry lacks a universally accepted, standardized framework for the quality control and evaluation of nanozymes, which complicates quality monitoring during production and the final release of the product. Clinical trials and the regulatory pathway Despite thousands of preclinical publications, the number of nanozymes that have entered formal clinical trials is exceedingly small. Iron oxide nanoparticles are one of the few classes with more extensive clinical trial experience, often benefiting from their initial use as MRI contrast agents. Currently, a novel IONP is undergoing a Phase II clinical trial for the diagnosis of hepatocellular carcinoma and is being explored for monitoring immunotherapy responses. The lack of clear regulatory guidelines and the scarcity of clinical trial data for novel nanozymes create a detrimental feedback loop. Regulatory uncertainty discourages investment in expensive trials, while the lack of trial data prevents regulatory bodies from developing evidence-based guidelines [235]. This cycle ensures that only nanozymes with simple structures or those being repurposed with existing clinical data can move forward with relative ease. Breaking this cycle will require a new collaborative model where regulators and developers work together prospectively on novel agents to generate the foundational data needed to build a modern regulatory framework. The vast majority of nanomedicines fail to cross the “valley of death” between promising preclinical results and successful clinical application. This failure is multifactorial, stemming from many of the challenges discussed in this report: over-reliance on non-predictive animal models, unforeseen long-term toxicities, insurmountable manufacturing and quality control hurdles, and the immense cost and uncertainty of the regulatory pathway. The most successful clinical nanoparticles have often followed a “repurposing” path, first gaining approval for a lower-risk application before their higher-risk therapeutic uses are explored. This may be the most pragmatic, albeit slow, strategy for introducing novel nanomaterials into the clinic. For example, iron oxide nanoparticles were first approved as MRI contrast agents, a process that generated a large volume of data on their safety and pharmacokinetics in humans. This existing data de-risked the subsequent development of the same nanoparticles for therapeutic applications, such as treating iron deficiency or monitoring immunotherapy. This suggests a feasible, incremental translational strategy: first introduce a novel nanoplatform as a diagnostic agent to establish a clinical safety record, and then leverage that record to “pivot” to therapeutic applications—a “Trojan Horse” strategy to help novel materials overcome initial regulatory barriers. To increase the success rate, the field needs to adopt a "'translation-first’ or ‘Quality by Design’ approach. This means that challenges such as manufacturing, safety, regulation, and patient heterogeneity must be considered from the earliest stages of research and development, rather than being treated as afterthoughts to scientific discovery. Lung-specific delivery barriers and pulmonary bio-nano interactions Unlike many other solid tumors, lung cancer develops within a highly specialized respiratory environment characterized by complex airway architecture, continuous airflow exposure, mucus coverage, pulmonary surfactants, and abundant resident immune cells. These unique anatomical and physiological features introduce additional challenges for nanozyme delivery, retention, and catalytic performance that are not fully encountered in other tumor systems. One important consideration is the choice of administration route. While most currently reported nanozyme systems rely on intravenous injection, inhalation-based delivery may offer several advantages for lung cancer therapy, including higher local drug concentration, reduced systemic exposure, and improved pulmonary targeting. However, inhaled nanozymes must overcome multiple airway barriers before reaching tumor tissue efficiently. The mucus layer covering the respiratory epithelium can hinder nanoparticle diffusion and promote rapid mucociliary clearance, thereby reducing local retention and therapeutic efficacy. Furthermore, pulmonary surfactants may adsorb onto nanozyme surfaces and alter their physicochemical properties, catalytic accessibility, and colloidal stability. Another major challenge is immune clearance by alveolar macrophages, which represent the first line of pulmonary immune defense. Nanozymes recognized as foreign particles may undergo rapid phagocytosis, resulting in shortened retention time and reduced catalytic activity within tumors. In addition, macrophage uptake and inflammatory activation may contribute to pulmonary toxicity or chronic immune responses after repeated administration. Surface engineering strategies such as PEGylation, biomimetic coating, charge modulation, or mucus-penetrating designs may help improve pulmonary compatibility and reduce immune clearance. Importantly, the pulmonary tumor microenvironment itself exhibits unique pathological characteristics. Chronic exposure to cigarette smoke, airborne pollutants, and inflammatory stimuli contributes to sustained oxidative stress and redox imbalance in lung tissue. Moreover, distinct molecular subtypes of lung cancer, such as EGFR-mutant immune-cold tumors and KRAS-driven inflammatory tumors, may exhibit different metabolic dependencies and immune microenvironments that influence nanozyme responsiveness. These observations suggest that future nanozyme systems for lung cancer should not simply target universal tumor hallmarks such as hypoxia or elevated H2O2, but should also integrate pulmonary delivery compatibility, respiratory biointerface interactions, and genotype-associated biological features into their design. Conclusion and perspectives The emergence of nanozymes marks a pivotal transition in oncological science, representing a conceptual shift from static, stoichiometric therapies to dynamic, catalytic interventions capable of actively reprogramming the tumor microenvironment (TME). Preclinical studies have convincingly demonstrated their versatility, with platforms that integrate chemodynamic, photothermal, and metabolic effects, often orchestrated with logic-gated precision. Yet, the stark gap between laboratory promises and the scarcity of clinical translation underscores the urgency for critical reflection. The continued evolution of the field will depend less on adding mechanistic complexity in animal models and more on resolving the fundamental paradoxes that have historically hindered the translation of nanomedicine and contributed to the “valley of death” between bench and bedside. The first paradox lies within the TME itself, which serves simultaneously as a therapeutic ally and an adversarial barrier. Many nanozyme designs exploit pathological signatures converting tumor-derived hydrogen peroxide into reactive radicals or triggering drug release in acidic conditions—yet these same features coincide with dense stromal matrices, high interstitial fluid pressure, and abnormal vasculature that severely limit nanoparticle penetration and substrate access. This is not merely a delivery issue but a biological contradiction. Future progress will require systems that first remodel or bypass these barriers, for example through vascular normalization, extracellular matrix modulation, or biomechanical re-engineering, before unleashing their catalytic functions. A second paradox reflects a “fidelity crisis” in preclinical-to-clinical translation. For decades, nanomedicine research has been guided by the Enhanced Permeability and Retention (EPR) effect, which appears robust in rapidly growing xenografts yet is inconsistent and often negligible in human tumors. This disconnect has produced systemic misalignment, where candidates selected for preclinical “success” are intrinsically unsuited for clinical reality. Moving forward requires more predictive models, including patient-derived organoids, immunocompetent orthotopic systems, and humanized mice, that more accurately capture the genetic heterogeneity, perfusion deficits, and immune complexity of human lung cancer. The third paradox emerges at the interface between synthetic design and biological identity. Nanozymes are meticulously engineered in the laboratory with defined physicochemical parameters, yet upon systemic administration, these characteristics are rapidly overridden by the adsorption of proteins, forming a corona that dictates biodistribution, clearance, immunogenicity, and therapeutic fate. It is this acquired biological persona not the engineered blueprint that governs clinical outcomes. Rather than resisting this transformation, future strategies must anticipate and exploit it, whether through biomimetic coating, intelligent surface chemistry, or camouflaging techniques that confer a “self-like” identity. These challenges must be interpreted against the backdrop of ongoing clinical progress in lung cancer. Adjuvant osimertinib has been shown to significantly extend both disease-free and overall survival in resected EGFR-mutant non-small cell lung cancer, setting a new benchmark for targeted perioperative therapy. Consolidation with durvalumab after chemoradiotherapy has extended long-term survival in unresectable stage III disease, and immune checkpoint blockade with pembrolizumab or nivolumab-based regimens has transformed the treatment of metastatic disease, producing durable survival tails in subsets of patients. Yet resistance, intracranial progression, and immune-related toxicities remain pervasive, emphasizing the need for enabling technologies that can modulate the TME, broaden response rates, and delay relapse. In this context, nanozymes should not be envisioned as standalone cytotoxic agents but as strategic enhancers of established therapies, with the capacity to oxygenate hypoxic lesions, exhaust antioxidant defenses, induce immunogenic cell death, and reprogram suppressive immune niches. Realizing this vision requires a paradigm shift from “design for efficacy” to “design for translation.” Scalable GMP manufacturing, long-term toxicology, and regulatory feasibility must be integrated at the earliest stages of development. Pragmatic clinical strategies may involve introducing nanozymes initially as diagnostic or imaging tools lower-risk applications that establish safety records before pivoting toward therapeutic use. Ultimately, the most impactful role for nanozymes in the future of lung cancer therapy will be as “microenvironment architects”: systems that dismantle stromal and vascular barriers, alleviate immunosuppression, and overcome metabolic resilience, thereby sensitizing tumors to the full potential of targeted therapy, immunotherapy, and radiotherapy. In this synergistic capacity, nanozymes hold their most realistic and profound promise, not as isolated disruptors but as powerful enablers of the therapeutic armamentarium that is reshaping the future of precision oncology. CRediT authorship contribution statement Fushuang Zheng: Conceptualization, Writing – original draft. Hongyan Zhang: Conceptualization, Data curation, Writing – original draft. Feng Guo: Formal analysis. Xiajie Wu: Investigation. Kuanbing Chen: Software, Supervision. Nana Li: Funding acquisition, Writing – review & editing. Hengyi Yan: Software, Validation. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments This work was supported by the Health Commission of Liaoning Province, Xingliao Talents Program Project (No. XLYC2412088) and China Medical University (CMU-24387). Contributor Information Xiajie Wu, Email: wuxiajie@163.com. Kuanbing Chen, Email: 19214258223@163.com. Nana Li, Email: linana@bjmu.edu.cn. Hengyi Yan, Email: yanhy163yhy@163.com. Data availability No data was used for the research described in the article. References Associated Data Data Availability Statement No data was used for the research described in the article.